MediWound (NASDAQ:MDWD) Research Coverage Started at began coverage on shares of MediWound (NASDAQ:MDWDGet Rating) in a report released on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on MDWD. Aegis lowered their target price on shares of MediWound from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, March 21st. Zacks Investment Research downgraded shares of MediWound from a “buy” rating to a “hold” rating in a report on Saturday, March 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, MediWound currently has an average rating of “Hold” and an average price target of $5.69.

Shares of NASDAQ:MDWD opened at $2.27 on Tuesday. MediWound has a 1-year low of $1.77 and a 1-year high of $6.22. The company has a market capitalization of $75.09 million, a P/E ratio of -4.63 and a beta of 1.40. The firm’s 50 day simple moving average is $2.11 and its two-hundred day simple moving average is $2.59.

MediWound (NASDAQ:MDWDGet Rating) last released its earnings results on Thursday, March 17th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. MediWound had a negative net margin of 57.03% and a negative return on equity of 3,540.43%. The firm had revenue of $5.49 million for the quarter, compared to the consensus estimate of $5.65 million. During the same quarter in the previous year, the firm earned ($0.06) earnings per share. As a group, research analysts expect that MediWound will post -0.39 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in MDWD. Marshall Wace LLP bought a new stake in MediWound in the first quarter worth $93,000. Morgan Stanley increased its position in MediWound by 33.9% during the first quarter. Morgan Stanley now owns 40,552 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 10,271 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in MediWound during the third quarter valued at $48,000. BOKF NA bought a new position in MediWound during the third quarter valued at $1,212,000. Finally, Jane Street Group LLC bought a new position in MediWound during the third quarter valued at $38,000. Institutional investors own 13.58% of the company’s stock.

About MediWound (Get Rating)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

See Also

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with's FREE daily email newsletter.